All News

RheumNow Podcast square

Mono- and Oligo- are Different (8.18.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.

Read Article
RheumNow Podcast square

Pizza and Rheumatoid Arthritis (8.11.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:

Read Article
RheumNow Podcast square

English for the Biologically-Challenged (8.4.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.

Read Article
RheumNow Podcast square

Scleroderma – Thick and Thin (6.30.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week from RheumNow.com. This week focuses on parodoxical psoriasis, scleroderma outcomes and subsets, and alopecia areata therapy.

Read Article
Clot.DVT_.VTE_.blood_.jpg

Low Risk of Venous Thromboembolism with IVIG and Dermatomyositis

Jack Cush, MD

A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG).

Read Article
RheumNow Podcast square

The Match Game (4.14.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, including Rheumatology success in the NRMP MATCH, Cocaine vasculitis and worrisome safety risks with Biologics and tsDMARDs.

Read Article
High mortality risk predictors in patients with anti-MDA5 dermatomyositis include: - rapidly progressive interstitial lung disease - anti-Ro52 antibody - age > 57 years (based on study of 126 MDA-5+ DM pts) https://t.co/VCyLhStFgX https://t.co/y3CyzOlwDt

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA: cutaneous hallmarks of dermatomyositis. Printable Patient education overview. https://t.co/VKsxT34lga https://t.co/VGaFmsYUrP

Links:

Dr. John Cush RheumNow ( View Tweet)
NEJM: 19 yoM w/ 3yr hx of Raynauds, periungual erythema. Nailfold capillaroscopy showed giant nailfold capillaries, branched & bushy neovascularized capillary loops & reduced capillary density; suggesting clinically amyopathic dermatomyositis https://t.co/Wvnp7wCajx

Links:

Dr. John Cush RheumNow ( View Tweet)

JAK inhibitors have been effective in refractory inflammatory myositis, all open label, but no controlled trials. #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

Treatment of IIM, MTX or AZA or IVIG are 1st line (with steroids). #EULAR2023 https://t.co/0B1zzeqm1L

Links:

Dr. John Cush RheumNow ( View Tweet)

Belimumab in adult inflamm myositis (IIM)? Small study 15 IIM pts recv ≥ 5 doses of belimumab or placebo; Treatment success (TIS ≥ 40) was more common with BEL (55% vs 33%) as was defined improvement (DOI: 33% vs 17%); not signif, but interesting! https://t.co/3xL0ylJbcs https://t.co/Oerf0yI4Jg

Links:

Dr. John Cush RheumNow ( View Tweet)
Belimumab in adult inflamm myositis (IIM)? Small study 15 IIM pts recv ≥ 5 doses of belimumab or placebo; Treatment success (TIS ≥ 40) was more common with BEL (55% vs 33%) as was defined improvement (DOI: 33% vs 17%); not signif, but interesting! https://t.co/CG9ClLHEW6 https://t.co/DPekHWjTsP

Links:

Dr. John Cush RheumNow ( View Tweet)
With the single cell RNA sequencing analysis being my more affordable (relatively) and widely used! Science is moving forward. Highlights in basic science and translational data #EULAR2023 @RheumNow https://t.co/sS7xLeNyLW
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 #POS1207 Promising therapy for dermatomyositis. Data from Stage One of Phase 2 RCT (N=18) showed Anti-IFN Beta mAb improved clinical, PROs, extra-muscular activity and reduced CK levels vs Placebo. No cases of HZV. One to watch out in the next few years @RheumNow https://t.co/Oh8sZlMzUt
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
JAK inhibitors have been effective in refractory inflammatory myositis, all open label, but no controlled trials. #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

Treatment of IIM, MTX or AZA or IVIG are 1st line (with steroids). #EULAR2023 https://t.co/TDKWxgrST0
Dr. John Cush RheumNow ( View Tweet)
Professor Ingrid Lundberg reviews the co associations amongst the inflammatory myopathies #EULAR2023 https://t.co/B9Idyz90Lh
Dr. John Cush RheumNow ( View Tweet)
Low Risk of Venous Thromboembolism with IVIG and Dermatomyositis A cohort study analyzed the risk of venous thromboembolism (VTE) in dermatomyositis (DM) patients treated with intravenous immunoglobulin (IVIG). https://t.co/tYOwsNaiGy https://t.co/Bpfft4J9MB

Links:

Dr. John Cush RheumNow ( View Tweet)
Japanese cohort study shows Lung cancer is more common in males w/ elder-onset dermatomyositis - risk increased by Smoking, anti-TIF1-γ-Abs and elevated MLR (monocyte to lymphocyte ratio) https://t.co/LlTkiWp7pb https://t.co/Bu9atnI8je

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×